Now We Know. Mobetron Is More.

IntraOp® Mobetron® saves time and enables more treatments in the operating room. It increases productivity and enhances collaboration among surgical and radiation oncologists. Breast cancer treatment with IORT is precise and flexible. The patient experience and outcomes are better. The data is conclusive and ASTRO agrees.

Boost or APBI: Mobetron Is Adaptable.

Deliver a Boost with Mobetron

One-minute Boost effectively augments radiation with fewer complications and greater control

IORT as a Boost

Single-Fraction APBI with Mobetron

Utilize the power of electrons in single-fraction accelerated partial breast irradiation (APBI)


Breast Cancer Clinical Studies and Registries

Intra-Operative Electron Boost and Hypofractionated Whole-Breast Irradiation During Breast-conserving Treatment (BCT) (HIOB)

The HIOB study concept is supposed to test the hypothesis whether such a combined schedule is superior (or iso-effective) towards "standard" RT in terms of local control and cosmetic outcome.

Read More

Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction

This phase II trial studies the side effects of intraoperative electron beam radiotherapy boost and to see how well it works in treating patients with stage I-II breast cancer undergoing surgery with reconstruction. Giving a single dose of electron beam radiation to the tumor cavity during the breast surgery before reconstruction may be a better way to kill tumor cells and shrink tumors.

Read More

Electron Based IORT Is The ONLY Single-Treatment Modality Affirmed By ASTRO APBI Consensus

The American Society of Radiation Oncology (ASTRO) issued an updated Consensus Statement on Accelerated Partial Breast Irradiation (APBI) in the journal Practical Radiation Oncology confirming the use of electron-beam IORT as an effective modality for the treatment of suitable patients with invasive breast cancer.

Furthermore, the ASTRO Consensus removes experimental status and recognizes the single fraction electron-beam IORT modality, validating Mobetron and distinguishing it from all other IORT treatment options available in the fight against cancer.

Webinar Series Explores New Perspectives in Breast Radiotherapy

Offering unique viewpoints in radiation and oncology, we join leading breast specialists—Jürgen Debus MD, PhD, and Jörg Heil, MD, PhD of Heidelberg University Hospital —as they dispel the myths associated IORT with electrons and compare its advantages for the patient, radiologists and the surgical team.

Advantages of single-treatment electron-beam IORT for low-risk breast cancer

Jürgen Debus, MD, PhD
Medical Director for the Department of Radiation Oncology and Radiation Therapy at Heidelberg University Hospital

Surgical procedures before and after IORT

Jörg Heil, MD, PhD
Head of the Breast Service at Heidelberg University Hospital, Germany and Consultant Oncoplastic Breast Surgeon

Mobetron Single Fraction APBI vs. Typical Treatment

Mobetron IORT Boost vs. Typical Treatment

Mobetron And The Economics Of Healthcare

At IntraOp, we recognize that the economics of healthcare is changing. Capital expenditures require a clear return on investment. Maybe your team or the facility had previous concerns about IORT for breast cancer. Or that your team made the case for other treatment technology based on the information available at the time.

We understand.

The team dynamic between oncological surgeons and radiation specialists can be tense and profit centers for facilities are a complex metric. So what if we told you we could help you with both?

Used by the leading cancer physicians and radiation oncologists in the most innovative and proven hospitals, clinics and academic centers in the world, the IntraOp Mobetron is the first portable, self-shielded electron linear accelerator designed to deliver Intraoperative Radiation Therapy (IORT) to cancer patients during surgery. All things combined, the precision, speed and physics of Mobetron presents a significant competitive advantage in the OR.

Oncologists who use Mobetron know that precision in dose and volume and uniformity in dosimetry are vital in the operating room. Combine that with shorter treatment cycles and minimized impact to healthy tissue, and Mobetron is a more effective, more productive, solution. We have the numbers to prove it.

You need every advantage in the fight against breast cancer. Mobetron could be your advantage.

It was pretty clear to us that treatment with the Mobetron was superior… Other forms of IORT employ photons, which have different penetration characteristics and aren’t as sparing of normal tissue as electrons are. The Mobetron has given us the ability to tailor treatment to the individual patient. Our intent is to cure them and to limit their side effects.”


Radiation Oncologist, Avera Regional Cancer Center, Sioux Falls, South Dakota

The Big Question: So Why Mobetron?

In a word, Mobetron is proven. Through clinical trials and confirmed by expert consensus.

The productivity of Mobetron equates to savings over the life of the machine. The Facility and Personal Utilization efficiencies offered by Mobetron, along with increased Earnings Per Hour and lower Total Costs of Ownership are worth reviewing. If you want specific data related to cost of operation and the financial advantages that Mobetron provides, please contact us. The numbers will do the talking.

Beyond the business, there are real surgical advantages to Mobetron.

The Clear Advantages With Mobetron


Mobetron improves visualization of the tumor bed thereby decreasing risk of radiation missing the tumor.


This alternative augments traditional radiation with fewer complications and fewer instances of recurrence.


Treatment generally requires only a few minutes, rather than weeks of pre- and post-surgery radiation sessions.


Safe, effective, flexible, portable, and proven technology delivers better outcomes and expands treatment offerings for physicians and facilities


Concentrated dose of radiation to a tumor site after it is removed assists in destroying residual microscopic tumor cells.


Expands options for oncoplastic reconstruction and enables surgeon to cosmetically enhance or reduce the breast during surgery.


Mobetron ensures the proper dose and the ability to treat a greater volume of cancerous tissue.


So that treatment begins when residual tumor cells are most active.

Taking The Next Step In Breast Cancer Treatment

At IntraOp, we are driven by innovations that can win the battle against cancer. Now we know more is possible with Mobetron. The world’s best oncologists tell us it’s a necessary component in their toolkit. Healthcare executives tell us Mobetron is a magnet for attracting new patients and the world’s greatest oncological talent. With Mobetron, we’re accelerating the cure.

Learn More about the Mobetron